華潤醫藥(03320.HK):與潛在發行相關的投標前程序通過北京產權交易所啟動
格隆匯10月30日丨華潤醫藥(03320.HK)發佈公吿,公司的全資附屬公司華潤醫藥商業集團有限公司建議根據《企業國有資產交易監督管理辦法》的相關規定,透過合法成立的股權交易所以公開投標方式發行新股份。潛在發行項下將予發行的新股份數目以及所籌集的所得款項金額將於考慮包括市場條件在內的各種因素後適時釐定。
於2023年10月30日,與潛在發行相關的投標前程序通過北京產權交易所啟動。華潤醫藥商業已於2023年10月30日在北京產權交易所網站發佈一份關於增資信息預披露申請書。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.